13.12.2022 09:25:28 CET | Monsenso |
Selskabsmeddelelse
Monsenso har sammen med et konsortium af partnere modtaget tildelingsbesked fra en fond om udvikling og test af et digitalt, AI-baseret, personligt terapikoncept til personer med mentale lidelser.
Selskabsmeddelelse nr. 15-2022
Monsenso (Nasdaq First North Growth Market Denmark : Ticker MONSO) er forpligtet til at offentliggøre denne information i henhold til EU Markedsmisbrugsforordning.
København, den 13. dec. 2022
Hidtil er digitale interventioner hovedsageligt blevet leveret i et format for alle patienter, hvor patienter får et fastlagt 6-12 ugers program, og hvor der opleves relativt høje frafaldsrater.
Med tildelingsbeslutningen vil Monsenso starte udarbejdelse af investeringsaftale med et konsortium af ledende forskere indenfor klinisk psykologi, internetbaseret terapi, sundhedsøkonomi og kunstig intelligens for at udvikle og lave kliniske forsøg med et nyt AI-baseret personligt terapikoncept baseret på Monsensos digitale sundhedsplatform. Det fireårige projekt forventes at starte i Q2-2023 og bidrage med kr 3,9 mio til Monsenso.
– Med dette projekt vil vi videreudvikle Monsenso-løsningens evne til at støtte og levere digitale behandlingsprogrammer tilpasset den enkelte og samtidig sikre at brugere ikke falder fra undervejs. Ved at udnytte patienters egne data og kunstig intelligens, er målet at give en inddragende og personlig behandling tilpasset patienternes situation, så de fremover tilbydes den rette behandling, på det rigtige tidspunkt og på en skalerbar måde, siger direktør Thomas Lethenborg, Monsenso.
Finansielle forventninger
Projektet ændrer ikke Monsensos finansielle forventninger til 2022, men forventes at bidrage til væksten i 2023 og fremefter.
Yderligere oplysninger:
Monsenso:
CEOThomas LethenborgTlf. +45 21 29 88 27E-mail: lethenborg@monsenso.com
Chairman of the boardPeter Mørch EriksenTlf. +45 51 99 66 00E-mail: petermorcheriksen@outlook.com
Certified Adviser:
Norden CEF A/SJohn NordenTlf. +45 20 72 02 00E-mail: jn@nordencef.dk
Om Monsenso
Monsenso er en innovativ virksomhed, som tilbyder en digital sundhedsløsning til brug for decentaliserede forsøg, patientmonitorering og behandlingsunderstøttelse. Vores mission er at bidrage til bedre sundhed til flere personer og lavere omkostninger ved at understøtte behandling digitalt og bedre udnytte patienters egne data. Vores løsning bidrager til optimering af behandlingen og giver et detaljeret overblik over patienters sundhed via indsamling af data om deres tilstand, adhærens og adfærd. Løsningen forbinder patienter, omsorgspersoner og behandlere for at muliggøre en personligt tilpasset behandling, distancebehandling samt tidlig intervention. Vi samarbejder med sundhedsvæsenet, medicinalindustrien og forskningsinstitutioner verden over i vores forsøg på at levere løsninger som passer ind i patienters og sundhedsprofessionelles hverdag. Få mere at vide på www.monsenso.com
Vedhæftninger
Download selskabsmeddelelse.pdf
Patient with smartphone.jpg
Clinician with clinical web portal.jpg
13.12.2022 09:25:28 CET | Monsenso |
Company Announcement
Monsenso and a consortium of partners have received a grant letter from a funding entity to develop and trial a new, AI-enabled personalised therapy concept for people with mental disorders.
Company announcement no. 15-2022
Monsenso (publ.) (Nasdaq First North Growth Market Denmark: Ticker MONSO) is obligated to publish the information in compliance with the EU Market Abuse Regulation.
Copenhagen, 2022.12.13
Currently, digital mental health interventions are largely developed as a one-size-fits-all approach, where patients get a fixed 6-12 week intervention and where drop-out rates are relatively high.
With the grant letter received, Monsenso is entering grant agreement negotiations with a consortium of leading researchers in clinical psychology, internet-based therapy, health economics and AI to develop and trial a new AI-enabled personalised care concept based on Monsenso’s platform. The four-year project is anticipated to start in Q2-2023 and is expected to contribute with DKK 3.9 mio to Monsenso.
– With this project, we will further develop our platform’s ability to deliver personalised digital treatment programs and to ensure optimal adherence to treatment. By leveraging patients’ own data and artificial intelligence, the aim is to be able to give more engaging and personalised care based on patients’ actual state, so that patients are offered the right treatment at the right time in a scalable way, says Thomas Lethenborg, CEO of Monsenso.
Full disclosure of the project details including consortium members, funding program and disorder area will be possible upon signature of the grant agreement, which is expected in Q1 of 2023.
Financial expectations
The project does not impact Monsenso’s financial expectations for 2022, but it is expected to contribute to the growth in 2023 and beyond.
Further information:
Monsenso:
CEOThomas LethenborgTel. +45 21 29 88 27E-mail: lethenborg@monsenso.com
Chairman of the boardPeter Mørch EriksenTel. +45 51 99 66 00E-mail: petermorcheriksen@outlook.com
Certified Adviser:
Norden CEF A/SJohn NordenTel. +45 20 72 02 00E-mail: jn@nordencef.dk
About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. We collaborate with health and social care, pharmaceuticals and leading researcher worldwide in our endevaours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit www.monsenso.com
Attachments
Download announcement as PDF.pdf
Patient with smartphone.jpg
Clinician with clinical web portal.jpg
